Details concerning the Rabeprazole Sodium combination medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments, ...

Details concerning the Rabeprazole Sodium(EC) combination medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments, ...

Rabeprazole sodium, a potent antisecretory compound, selectively inhibits gastric acid secretion by targeting the H+ and K+ ATPase at the surface of gastric parietal cells. It has demonstrated ...

The US Food and Drug Administration (FDA) has approved the first generic versions of Aciphex (rabeprazole sodium; Eisai) delayed-release tablets for the treatment of gastroesophageal reflux disease ...

March 13, 2007 — The US Food and Drug Administration (FDA) has approved first-time generic formulations for rabeprazole sodium 20-mg delayed-release tablets and ranitidine HCl 15-mg/mL oral ...

Co announces that the FDA has granted final approval for the Company's Abbreviated New Drug Application for Rabeprazole Sodium Delayed-Release Tablets, 20 mg. TEVA's Rabeprazole Sodium Delayed-Release ...

This leaflet answers some common questions about RABEPRAZOLE MYLAN. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines ...

WOODCLIFF LAKE, N.J., Nov. 30, 2012 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review Eisai's New Drug Application (NDA) for ...

Akums Drugs & Pharmaceuticals Ltd., one of the country’s largest India-CDMO serving the Indian domestic pharmaceutical industry, has announced the launch of Rabeprazole + Levosulpiride SR Capsules.

Akums Drugs & Pharmaceuticals Ltd. on Monday announced that it has launched Rabeprazole + Levosulpiride SR Capsules. Approved by the Drug Controller General of India (DCGI), the company claims this ...

Pulmonary adverse drug reactions in patients treated with gemcitabine and a combination of gemcitabine and a taxane No significant financial relationships to disclose. This is an ASCO Meeting Abstract ...